News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the […]
<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
Pfizer and SINOPHARM have entered into a new partnership to promote antifungal drug Diflucan in China. The collaboration also includes plans to work together on future Pfizer product launches in the Chinese market. The agreement focuses on supply chain optimization, resource integration, and improving commercial execution across China. Pfizer (NYSE:PFE) is using this new agreement with SINOPHARM to deepen its presence in one of the world’s most important pharmaceutical markets. With the...
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"
The move could expand Novo's reach in a key obesity-drug market.
Pfizer, Altria, Newmont, Koil Energy and Stratus Properties are featured for their growth drivers, challenges and recent stock performance.
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Altria Group, Inc. (MO) and Newmont Corp. (NEM), as well as two micro-cap stocks, Koil Energy Solutions, Inc. (KLNG) and Stratus Properties Inc. (STRS).
Pfizer's business may be in better shape than investors think.
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for obesity. The data show proof of concept with favorable tolerability and low reported adverse events in the trial setting. Pfizer has started Phase 3 trials and outlined a broader clinical program for berobenatide as part of its late-stage obesity pipeline. For investors tracking NYSE:PFE, this update offers a clearer view of how Pfizer is positioning itself in the...
With an annual dividend yield of 6.57%, Pfizer Inc. (NYSE:PFE) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]
Passive income arrives while you sleep, commute, or vacation. That appeal drives dividend investing: a paycheck every quarter regardless of market conditions or work hours. Layoff announcements have rattled white-collar industries through the first half of 2026, and essentials costs climb faster than most household raises. Building a cash-flowing portfolio is one of the few ... 3 Stocks With a Yield Over 6% For Passive Income Investors
Pfizer Inc. (NYSE:PFE) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is […]
While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.
Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
Pfizer (NYSE:PFE) reported Phase 3 data for BRAFTOVI in BRAF V600E-mutated metastatic colorectal cancer and TALZENNA in HRR-mutated metastatic prostate cancer. The company presented the long term results at ASCO and published them in leading medical journals. The data show meaningful survival benefits in high-need cancer populations and reinforce Pfizer’s oncology positioning. For investors following NYSE:PFE, these oncology readouts add another piece to the story that has recently centered...
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.
Pfizer (NYSE:PFE) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that ... This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees
At $25.60, Pfizer (NYSE:PFE) sits in Hold territory on Wall Street’s consensus. The headline 6.7% dividend yield is reason to pause rather than pounce. A payout that fat usually reflects a market pricing in trouble, and the under-the-radar concern is whether stretched operating cash flow can fund both the dividend and the debt stack from ... A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25